Curaleaf products display at Curaleaf store in Queens in New York, U.S., on Thursday, Oct.18, 2018. (Photo: Jeenah Moon/Bloomberg)
Federal regulators last Tuesday threatened cannabis giant Curaleaf with possible legal action for allegedly making unsubstantiated medical claims about the cannabidiol, or CBD, products on its website and on social media.
In a public letter, the U.S. Food and Drug Administration gave Massachusetts-based Curaleaf about two weeks to explain what it has done to correct alleged violations, including website claims that CBD has "properties that counteract the growth of spread of cancer" and is "linked to the effective treatment of Alzheimer's disease."
Want to continue reading?
Become a Free PropertyCasualty360 Digital Reader
Your access to unlimited PropertyCasualty360 content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking insurance news and analysis, on-site and via our newsletters and custom alerts
- Weekly Insurance Speak podcast featuring exclusive interviews with industry leaders
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the employee benefits and financial advisory markets on our other ALM sites, BenefitsPRO and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Mike Scarcella
Mike Scarcella is a senior editor in Washington on ALM Media's regulatory desk. Contact him at [email protected]. On Twitter: @MikeScarcella. Mike works on a slate of newsletters: Supreme Court Brief | Higher Law | Compliance Hot Spots | Labor of Law.
